Eye Movement Impairment Recovery in a Gaucher Patient Treated with Miglustat

In Gaucher Disease (GD) the enzyme (imiglucerase) replacement therapy (ERT) is not able to stop the progression of the neurological involvement, while the substrate reduction therapy (SRT), performed by N-Butyldeoxynojirimycin (miglustat), is an alternative that should be evaluated. Two sisters, pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Accardo, Agostino, Pensiero, Stefano, Ciana, Giovanni, Parentin, Fulvio, Bembi, Bruno
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989716/
https://www.ncbi.nlm.nih.gov/pubmed/21152212
http://dx.doi.org/10.1155/2010/358534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989716/
https://www.ncbi.nlm.nih.gov/pubmed/21152212
http://dx.doi.org/10.1155/2010/358534

Ejemplares similares